325 related articles for article (PubMed ID: 20394723)
1. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice.
Chen X; Lai J; Pan Q; Tang Z; Yu Y; Zang G
Vaccine; 2010 May; 28(23):3913-9. PubMed ID: 20394723
[TBL] [Abstract][Full Text] [Related]
2. HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice.
Wang S; Han Q; Zhang N; Chen J; Liu Z; Zhang G; Li Z
Immunol Lett; 2010 Jan; 127(2):143-9. PubMed ID: 19883689
[TBL] [Abstract][Full Text] [Related]
3. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo.
Song L; Zhuo M; Tang Y; Chen X; Tang Z; Zang G
Int Immunopharmacol; 2014 Nov; 23(1):1-7. PubMed ID: 25135878
[TBL] [Abstract][Full Text] [Related]
6. Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo.
Chen X; Tang Y; Zhang Y; Zhuo M; Tang Z; Yu Y; Zang G
Lab Invest; 2014 May; 94(5):478-90. PubMed ID: 24614195
[TBL] [Abstract][Full Text] [Related]
7. [The immunization effects of HBV core antigen and surface antigen fusion protein in mice].
Li L; Tian YJ; Shen H; Zhao XP; Yang DL
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):275-9. PubMed ID: 19403026
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
[TBL] [Abstract][Full Text] [Related]
9. [HBcAg-specific CTL response induced by PTD-HBcAg fusion protein to inhibit HBV replication in vitro].
Chen XH; Pan QC; Yu YS; Tang ZH; Zang GQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Apr; 25(4):289-92. PubMed ID: 19351491
[TBL] [Abstract][Full Text] [Related]
10. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice.
Zhuo M; Song L; Tang Y; Dai S; Chen X; Yu Y; Zang G; Tang Z
Mol Med Rep; 2015 Sep; 12(3):3591-3598. PubMed ID: 26004262
[TBL] [Abstract][Full Text] [Related]
12. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
13. [Immune response to HSP70-HBcAg(18-27) complex in HBV transgenic mice].
Hu HD; Hu P; Chen GL; Peng ML; Chen M; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 Jan; 15(1):28-31. PubMed ID: 17244455
[TBL] [Abstract][Full Text] [Related]
14. The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellularly delivered CTL epitopes via cytoplasmic transduction peptide.
Chen X; Liu H; Tang Z; Yu Y; Zang G
Acta Biochim Biophys Sin (Shanghai); 2013 Mar; 45(3):203-12. PubMed ID: 23299079
[TBL] [Abstract][Full Text] [Related]
15. H-2 Kd-restricted hepatitis B virus-derived epitope whose specific CD8+ T lymphocytes can produce gamma interferon without cytotoxicity.
Chen A; Wang L; Zhang J; Zou L; Jia Z; Zhou W; Wan Y; Wu Y
J Virol; 2005 May; 79(9):5568-76. PubMed ID: 15827171
[TBL] [Abstract][Full Text] [Related]
16. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96.
Yan J; Liu X; Wang Y; Jiang X; Liu H; Wang M; Zhu X; Wu M; Tien P
J Gene Med; 2007 Feb; 9(2):107-21. PubMed ID: 17256801
[TBL] [Abstract][Full Text] [Related]
18. Hot-spot mutations in hepatitis B virus core gene: eliciting or evading immune clearance?
Liu Z; Luo K; He H; Hou J
J Viral Hepat; 2005 Mar; 12(2):146-53. PubMed ID: 15720529
[TBL] [Abstract][Full Text] [Related]
19. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
Li X; Yang X; Li L; Liu H; Liu J
Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
[TBL] [Abstract][Full Text] [Related]
20. Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice.
Qing Y; Chen M; Zhao J; Hu H; Xu H; Ling N; Peng M; Ren H
Vaccine; 2010 Jun; 28(26):4301-7. PubMed ID: 20430121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
